We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biosimilars are absolutely a hotspot of the global pharmaceutical R&D field in recent years, especially in the patent cliff era. There have been biosimilars sold in the Europe since 2006, but the U.S. did not fill in gaps in system of relevant regulation